Biosimilars: what the oncologist should know

Future Oncology
Marc ThillGary H Lyman

Abstract

As originator biologic medicines lose patent protection, some biopharmaceutical companies are focusing on developing similar versions of these costly and complex therapies with a goal of providing more affordable treatment options. Many of these molecules, known as biosimilars, are now approved worldwide and several more are expected to be introduced in the near future. As more biosimilars become available, it is important for clinicians to become familiar with this new category of products and understand how biosimilars are developed, how their development differs from that of originator biologics and how they differ from generics. This review aims to provide the practicing clinician with the knowledge needed to understand biosimilars, along with some guidance on their use in treating oncologic diseases.

References

Nov 14, 2001·Seminars in Oncology·J BaselgaJ Arribas
Sep 9, 2006·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Martin Kuhlmann, Adrian Covic
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chia C Portera, Sandra M Swain
Sep 19, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José Baselga, Josep Tabernero
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil L Spector, Kimberly L Blackwell
Mar 31, 2010·Seminars in Hematology·George J Weiner
Jun 28, 2011·Arthritis and Rheumatism·Robert A Colbert, Bruce N Cronstein
Jan 5, 2013·Expert Opinion on Biological Therapy·Paul J Declerck
May 30, 2013·Bioengineered·Ivo AbrahamKaren MacDonald
Feb 25, 2014·Breast Cancer Research and Treatment·J CortésV Diéras
Oct 10, 2014·Blood·Martina WeiseChristian K Schneider
Mar 3, 2015·Annals of Surgical Oncology·Patricia Cortazar, Charles E Geyer
Sep 19, 2015·Pharmaceutical Research·Paul DeclerckPauline M Rudd
Feb 14, 2016·The AAPS Journal·Shein-Chung ChowHe Bai
Nov 1, 2016·Advances in Therapy·Hillel CohenJonathan Uy
Apr 26, 2017·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Richard MarkusPrimal Kaur
Jan 24, 2018·Journal of the European Academy of Dermatology and Venereology : JEADV·P YamauchiR Warren
Feb 15, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanRichard L Schilsky
Aug 16, 2018·The New England Journal of Medicine·Gary H LymanR Donald Harvey
Aug 21, 2018·The New England Journal of Medicine·George Y Tang

❮ Previous
Next ❯

Citations

Aug 17, 2020·International Journal of Environmental Research and Public Health·Vesa HalimiAleksandra Grozdanova
Sep 11, 2019·Cancer Investigation·Gary H Lyman, Nicole Kuderer
Jan 12, 2021·Oncology and Therapy·Hans-Christian KolbergVladimir Hanes
Aug 31, 2020·Regulatory Toxicology and Pharmacology : RTP·Khalid K Al-KinaniRodeina Challand
Dec 19, 2020·Oncology and Therapy·Jerome Goldschmidt, Vladimir Hanes
Jun 15, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Aayushi S DitaniRakesh K Tekade

❮ Previous
Next ❯

Methods Mentioned

BETA
Glycosylation

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.